Sign In
Buy HIMS
$27.77
+0.730 (+2.70%)
At Close: Jul 31, 2026
Hims & Hers Falls on Planned $300 Million Convertible Debt Offering
12:56pm, Monday, 18'th May 2026
Hims and Hers Health (HIMS, Financials) fell after the company proposed a private offering of $300 million in convertible senior notes due 2032.The company said p
Forget Hims. Its CEO Dumped 436,000 Shares Before a 1,266% Earnings Miss.
09:22am, Monday, 18'th May 2026
Hims & Hers (NYSE:HIMS) is dominating headlines this week because the GLP-1 darling just delivered one of the ugliest quarters in the telehealth sector's short history, and bargain hunters are circlin
7 Healthcare AI Stocks Under $50 With Huge Upside Potential
07:35am, Monday, 18'th May 2026
Healthcare AI stocks have been hammered in 2026, with several names down 30% to 65% year to date even as their underlying platforms keep maturing.
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS) today announced its intention to offer, subject to market and other conditions, $300 milli
Hims & Hers Health: GLP-1 Drama Ending Signals Return To Growth
02:00pm, Sunday, 17'th May 2026
Hims & Hers Health has returned to growth mode after volatility from the GLP-1 transition, yet trades near multi-year lows. The online health platform guided up 2026 revenues to $3B, exceeding consens
DOCS vs. HIMS: Which Stock Is the Better Value Option?
12:40pm, Friday, 15'th May 2026
Investors interested in stocks from the Medical Info Systems sector have probably already heard of Doximity (DOCS) and Hims & Hers Health, Inc. (HIMS). But which of these two companies is the best opt
HIMS Stock Dips 14.3% Since Q1 Earnings: Should You Still Hold or Sell?
11:16am, Friday, 15'th May 2026
Hims & Hers faces profit pressure in first-quarter 2026, though subscribers increase and a Novo Nordisk GLP-1 partnership broadens weight-loss care.
Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should Know
10:00am, Friday, 15'th May 2026
Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.
Hims & Hers Health: The Stock Is On Sale, Buy It
09:56am, Friday, 15'th May 2026
Hims & Hers Health delivered a misunderstood Q1-26, raising FY-26 guidance and reaffirming 2030 revenue and EBITDA targets despite negative sentiment. The transition from compounded to branded GLP-1s
Hims & Hers Stock Drops After Earnings: Buying Opportunity or Warning Sign?
05:05am, Friday, 15'th May 2026
Hims and Hers continues growing rapidly, but shrinking margins and rising costs are beginning to test the company's long-term profitability story.
Is Hims and Hers Health Stock a Buy After Its Latest Dip?
12:30pm, Thursday, 14'th May 2026
Hims upped its revenue forecast but is seeing major margin compression. The company could potentially have a big opportunity with peptides, pending the lifting of an FDA ban.
Hims & Hers Health Is Likely Dead Money
11:45am, Thursday, 14'th May 2026
Hims & Hers Health, Inc.'s Q1 results confirmed margin compression and weak unit economics from the shift to branded GLP-1 drugs, as I explained would happen in my previous post. Subscriber growth slo
BofA Cuts Hims & Hers Price Target as Mixed Quarter Resets Street Expectations
11:15am, Wednesday, 13'th May 2026
Hims & Hers Health (NYSE:HIMS) absorbed another analyst downgrade.
Hims & Hers Health: The Market Is Selling The Wrong Quarter
10:18am, Wednesday, 13'th May 2026
I'm upgrading Hims & Hers Health to a buy as the branded GLP-1 transition outpaces my expectations, in turn restores growth visibility. HIMS shipped 125,000 Wegovy units in six weeks, and management i
Hims & Hers Health: The Real Story Begins
06:09pm, Tuesday, 12'th May 2026
Hims & Hers Health raised FY2026 revenue guidance to $2.8-$3.0 billion despite reporting a heavily distorted quarterly EPS loss. More than 125,000 Wegovy shipments in six weeks suggest Novo conversion
